Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity - eBioMedicine
Por um escritor misterioso
Descrição
Frontiers Progress in construction of mouse models to investigate the pathogenesis and immune therapy of human hematological malignancy
RCSB PDB - 8BYU: Crystal Structure of HexaBody-CD38 Fab in complex with CD38
IJMS, Free Full-Text
Biomedicines, Free Full-Text
Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity - eBioMedicine
Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. - Abstract - Europe PMC
Frontiers Progress in construction of mouse models to investigate the pathogenesis and immune therapy of human hematological malignancy
Progress in construction of mouse models to investigate the pathogenesis and immune therapy of human hematological malignancy - Frontiers
CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells. - Abstract - Europe PMC
Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity - eBioMedicine
AAV-CRISPR-Cas13 eliminates human enterovirus and prevents death of infected mice - eBioMedicine
PDF) Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors
Frontiers Therapeutic strategies for gastric cancer targeting immune cells: Future directions
CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells. - Abstract - Europe PMC
Multi-targeted immunotherapeutics to treat B cell malignancies - ScienceDirect
de
por adulto (o preço varia de acordo com o tamanho do grupo)
